The Global Diabetic Neuropathy Market is expected to grow at a CAGR of 5.9% during the forecasting period (2020-2027).
Diabetic Neuropathy (DN) refers to nerve fiber damage caused by diabetes. It is a common yet serious complication of diabetes.
Between 60% to 70% of people with diabetes develop some form of neuropathy. The highest rates of neuropathy are among people who have had the disease for over 25 years.
According to the International Diabetes Federation (IDF), the number of people with diabetes worldwide was estimated at 366 million in 2011 and is expected to rise to 522 million in 2030.
This dramatically increasing prevalence of diabetes, which is likely to double over the next 10 years, will greatly increase the patient pool for DN.
Thus, this represents a huge market opportunity for the global Diabetic Neuropathy market. In addition to growing awareness and diagnosis of type 2 diabetes, factors such as aging population, the rise in obesity, and the increasingly sedentary lifestyles will further drive the sales in the DN market.
However, the diabetic neuropathy market is largely dominated by generics, which raises the barrier to entry for novel drug therapies, thereby acting as a growth deterrent to the global Diabetic Neuropathy market.
Currently, there are no approved disease-modifying therapies for different forms of diabetic neuropathy. An incomplete understanding of the pathophysiology of DN has made drug development challenges.
A number of potential novel candidates are currently being evaluated for the effective treatment of DN.
Diabetic neuropathy imposes a significant burden on the healthcare systems of developed economies.
Depending upon the part of a body where the nerve damage occurs, DN is classified into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy.
Peripheral Neuropathy, which affects the feet and hands, accounts for the largest share in the DN market. This is because peripheral neuropathy is the most common form of DN with 60-70% of diabetic patients having this type of neuropathy.
An estimated 15-18 million Americans suffer from peripheral neuropathy, representing over one-third of all neuropathies.
Segmentation based on treatment type includes pharmacological approach and non-pharmacological management. Pharmacological approach is further sub-segmented into drug classes such as analgesic, antidepressant, and anticonvulsants.
Since pharmacotherapy is not entirely successful, non-pharmacological treatment options such as electrostimulation, Electromagnetic field treatment, low-intensity laser treatment are also considered.
Lastly, the market is classified based on the distribution channel into Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy.
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
North America is the largest market for Diabetic Neuropathy owing to the highest prevalence of diabetes in the adult population, noted at 7.9%. The US itself represents a huge market opportunity as the US obesity epidemic will lead to an increased prevalence of type 2 diabetes, and consequently, an increased prevalence of DN.
The North America market for Diabetic Neuropathy was valued at USD X billion in 2017 and is expected to grow at a CAGR of X% over the forecast period.
Asia Pacific region is expected to be the fastest growing region. The prevalence of type 1 and type 2 diabetes has been rapidly increasing in developing countries due to dynamic and ongoing socioeconomic transition and the ensuing changes in lifestyle factors.
Out of the total people with diabetes across the globe, more than 60% live in Asia, with almost one-half in China and India combined.
The report profiles the following companies in the Diabetic Neuropathy market Pfizer, Eli Lilly, Lupin Limited, Glenmark Pharmaceuticals, Astellas Pharma and so on.
The scope of The Report:
By Treatment Type
By Distribution Channel
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific).Europe (Germany, France, The UK, Italy, Spain, Rest of Europe).
North America (The USA, Canada, Mexico).
South America (Brazil, Argentina, Rest of South America).
Rest of the World.
Visualize the composition of the Diabetic Neuropathy market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
Identify commercial opportunities in Diabetic Neuropathy by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the Diabetic Neuropathy market level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key Diabetic Neuropathy of all major market players
Equipment Suppliers/ Buyers
Service Providers/ Buyers
Industry Investors/Investment Bankers
1.1 Research Methodology
1.2 Scope of the Report
2.1 Key Trends & Developments
3.1 Market Drivers
3.1.1Increasing prevalence and diagnosis of diabetes
3.1.2 Increasing DN incidence due to the growing elderly population
3.1.3 Approval of novel therapies in the pipeline
3.2 Market Restraints
3.2.1 DN market is dominated by generics, which raises the barrier to entry for novel drug therapies
3.3 Threats and Opportunities
3.4 Porters 5 Forces
4.1. Diabetic Neuropathy Market By Type
4.1.1 Peripheral Neuropathy
4.1.2 Autonomic Neuropathy
4.1.3 Proximal Neuropathy
4.1.4 Focal Neuropathy
4.2 Diabetic Neuropathy Market- By Treatment Type
4.2.1 Pharmacological Treatment
22.214.171.124.1 Tricyclic Antidepressants (TCAs)
126.96.36.199.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
188.8.131.52.3 Serotonin Reuptake Inhibitors (SSRIs)
184.108.40.206.1 Calcium alpha-2-delta anticonvulsants
220.127.116.11.2 Sodium channel anticonvulsants
18.104.22.168.1 Opioid Analgesics
22.214.171.124.2 Topical Analgesics
4.2.2 Non-Pharmacological Treatment
126.96.36.199 Transcutaneous Electrical Nerve Stimulation (TENS)
188.8.131.52 Frequency Pulsed Magnetic therapy
184.108.40.206 Low-intensive laser therapy
220.127.116.11 Monochromatic infrared light/ Monochromatic infrared energy (MIRE)
4.3 Diabetic Neuropathy Market- By Distribution Channel
4.3.3 Retail Pharmacy
4.3.4 Online Pharmacy
5.1. North America
5.1.1. The USA
5.2.3. The UK
5.2.6. Rest of Europe
5.3. Asia Pacific
5.3.5. Rest of Asia Pacific
5.4. South America
5.4.3. Rest of South America
5.5 Rest of the World
6.1. Market Share Analysis
6.2. Mergers and Acquisitions Analysis
6.3. New Product Launches
7.1 Astellas Pharma Inc.
7.2 Boehringer Ingelheim GmbH
7.3 Eli Lilly
7.4 Endo Health Solutions
7.5 Glenmark Pharmaceuticals
7.7 Janssen Pharmaceuticals
7.8 Johnson and Johnson
7.9 Lupin Limited
7.10 NeuroMetrix, Inc.
7.11 Novartis AG
7.12 Pfizer, Inc
8.2 List of Tables
8.3 Expert Panel Validation
8.5 Contact Us
*Note: Additional company profiles will be included on client request.
Get your FREE SAMPLE PROPOSAL with a single click!